Anika Therapeutics, Inc. (ANIK)
13.85
-0.33
(-2.33%)
USD |
NASDAQ |
Mar 20, 16:00
13.86
+0.01
(+0.07%)
After-Hours: 20:00
Anika Therapeutics Research and Development Expense (Quarterly) : 6.452M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BioCryst Pharmaceuticals, Inc. | 40.47M |
| Lantheus Holdings, Inc. | 47.48M |
| TELA Bio, Inc. | 2.348M |
| Plus Therapeutics, Inc. | 2.941M |
| BioStem Technologies, Inc. | 1.958M |